دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Endocrine disruptors—the lessons (not) learned
doi : 10.1016/S1470-2045(21)00597-0
Volume 22, Issue 11, November 2021, Page 1483
Streamlining the WHO cervical cancer elimination goal
Diane MHarperaLaura SRozekb
doi : 10.1016/S1470-2045(21)00487-3
Volume 22, Issue 11, November 2021, Pages 1484-1485
CONFIRMing single-drug immune checkpoint blockade efficacy in mesothelioma
Anna KNowakabc
doi : 10.1016/S1470-2045(21)00516-7
Volume 22, Issue 11, November 2021, Pages 1485-1487
Drug development in metastatic prostate cancer: lessons from ACIS
UmangSwamiaNeerajAgarwala
doi : 10.1016/S1470-2045(21)00458-7
Volume 22, Issue 11, November 2021, Pages 1487-1488
Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer
Eliza WBeala
doi : 10.1016/S1470-2045(21)00543-X
Volume 22, Issue 11, November 2021, Pages 1488-1490
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease
Kevin MEliasaAntonioBragabcNeil SHorowitzaRoss SBerkowitza
doi : 10.1016/S1470-2045(21)00524-6
Volume 22, Issue 11, November 2021, Pages 1490-1491
Reimagining prostate cancer screening: the IMPACT of germline mutations
GiorgioGandagliaabAlbertoBrigantiabFrancescoMontorsiab
doi : 10.1016/S1470-2045(21)00571-4
Volume 22, Issue 11, November 2021, Pages 1491-1492
Addressing breast cancer mortality in low-income and middle-income countries: if you can't measure it, it doesn't exist
EmilyHeera
doi : 10.1016/S1470-2045(21)00519-2
Volume 22, Issue 11, November 2021, Pages 1493-1494
The thin border between individual and collective ethics: the downside of GDPR
CelesteCagnazzoab
doi : 10.1016/S1470-2045(21)00526-X
Volume 22, Issue 11, November 2021, Pages 1494-1496
Nuclear medicine theranostics comes of age
KenHerrmannabcBernd JoachimKrausedBorisHadaschikbcJolantaKunikowskaeHendrikvan PoppelfJamesN'DowghOliverSartorijWim J GOyenklmn
doi : 10.1016/S1470-2045(21)00540-4
Volume 22, Issue 11, November 2021, Pages 1497-1498
A nodal risk cutoff for whole pelvic radiotherapy for prostate cancer?
VedangMurthyaPriyamvadaMaitrea
doi : 10.1016/S1470-2045(21)00530-1
Volume 22, Issue 11, November 2021, Page e467
Radiotherapy with genomic-adjusted radiation dose
TairoKashiharaaKenichiKashiharaab
doi : 10.1016/S1470-2045(21)00541-6
Volume 22, Issue 11, November 2021, Page e468
Radiotherapy with genomic-adjusted radiation dose
Hima BinduMusunuruaAndrewKelleraSushilBeriwalbc
doi : 10.1016/S1470-2045(21)00583-0
Volume 22, Issue 11, November 2021, Page e469
Radiotherapy with genomic-adjusted radiation dose – Authors' reply
Jacob GScottabGeoffreySedoraJessica AScarboroughabMichael WKattancJavier FTorres-Rocad
doi : 10.1016/S1470-2045(21)00601-X
Volume 22, Issue 11, November 2021, Pages e470-e471
Correction to Lancet Oncol 2020; 21: 763–75
doi : 10.1016/S1470-2045(21)00587-8
Volume 22, Issue 11, November 2021, Page e472
Correction to Lancet Oncol 2021; 22: 1360–62
doi : 10.1016/S1470-2045(21)00598-2
Volume 22, Issue 11, November 2021, Page e472
Correction to Lancet Oncol 2021; 22: 1468–82
doi : 10.1016/S1470-2045(21)00586-6
Volume 22, Issue 11, November 2021, Page e472
Correction to Lancet Oncol 2021; 22: 1573–81
doi : 10.1016/S1470-2045(21)00599-4
Volume 22, Issue 11, November 2021, Page e472
ESMO Congress 2021
CherylLai
doi : 10.1016/S1470-2045(21)00567-2
Volume 22, Issue 11, November 2021, Pages 1499-1500
British American Tobacco: allegations of malpractice
Talha KhanBurki
doi : 10.1016/S1470-2045(21)00568-4
Volume 22, Issue 11, November 2021, Page 1501
Cancer care crisis in Nigeria amid doctors' strike
ManjulikaDas
doi : 10.1016/S1470-2045(21)00569-6
Volume 22, Issue 11, November 2021, Page 1502
WHO Essential Medicines Committee spotlights unaffordable drugs
BryantFurlow
doi : 10.1016/S1470-2045(21)00575-1
Volume 22, Issue 11, November 2021, Page 1503
Poor cancer care in Zimbabwe
ManjulikaDas
doi : 10.1016/S1470-2045(21)00576-3
Volume 22, Issue 11, November 2021, Page 1504
The challenges of inadequate financial support for Australians with cancer
AdithyaBalasubramanian
doi : 10.1016/S1470-2045(21)00600-8
Volume 22, Issue 11, November 2021, Page e473
They are our greatest teachers
Edward ChristopherDeea
doi : 10.1016/S1470-2045(21)00054-1
Volume 22, Issue 11, November 2021, Pages 1505-1506
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
COVIDSurg Collaborative*
doi : 10.1016/S1470-2045(21)00493-9
Volume 22, Issue 11, November 2021, Pages 1507-1517
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
ParthaBasuMDaSylla GMalviPhDbSmitaJoshiPhDcNeerjaBhatlaMDdRichardMuwongePhDaEricLucasMScaYogeshVermaMDePulikkottil OEsmyMDfUsha Rani ReddyPoliDNBgAnandShahMDhEricZomawiaMDiProfSharmilaPimpleMDjKasturiJayantMScbSanjayHingmireMBAbArunaChiwateCT [IAC]bUmaDivateMDcShachiVashistBHMSdGauraviMishraMDjRadhikaJadhavMSWcProfMaqsoodSiddiqiPhDkSubhaSankaranMCAlPriya RameshPrabhuPhDmThiraviam Pillai Rameshwari AmmalKannanMSclRintuVargheseMSclSurendra SShastriMDnDevasenaAnantharamanPhDlTarikGheitPhDaMassimoTommasinoPhDaCatherineSauvagetMDaProfM RadhakrishnaPillaiFRCPathlRengaswamySankaranarayananMDo
doi : 10.1016/S1470-2045(21)00453-8
Volume 22, Issue 11, November 2021, Pages 1518-1529
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
ProfDean AFennellFRCPabSeanEwingsPhDcProfChristianOttensmeierFRCPfRaffaeleCalifanoMDgGerard GHannaFRCRhKayleighHillMSccSarahDansonFRCPiNicolaSteeleFRCPjMavisNyedLucyJohnsoncJoanneLordPhDeCalleyMiddletonBAcProfPeterSzlosarekMRCPkSamChanMRCPlAartiGabaMScaLizDarlisonMScbmPeterWells-JordanFIBMSbCathyRichardsFRCPathbCharlottePoilePhDaJason FLesterFRCRnGarethGriffithsPhDcon behalf of the
doi : 10.1016/S1470-2045(21)00471-X
Volume 22, Issue 11, November 2021, Pages 1530-1540
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
ProfFredSaadMDaProfEleniEfstathiouMDbProfGerhardtAttardMDcThomas WFlaigMDdFabioFrankeMDeOscar BGoodmanJrMDfProfStéphaneOudardMDgProfThomasSteuberMDhProfHiroyoshiSuzukiMDiDaphneWuPhDjKesavYeruvaPhDjPeterDe PorreMDkProfSabineBrookman-MayMDjlSusanLiPhDmJinhuiLiPhDnShibuThomasPhDmKatherine BBevansPhDoSuneel DMundlePhDpSharon AMcCarthyBSpDana ERathkopfMDqfor the
doi : 10.1016/S1470-2045(21)00402-2
Volume 22, Issue 11, November 2021, Pages 1541-1559
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
ChanghoonYooMDaKyu-pyoKimMDaJae HoJeongMDaIlhwanKimMDfMyoung JooKangMDfJaekyungCheonMDeByung WoogKangMDgHyewonRyuMDhJi SungLeePhDbcKyung WonKimMDdProfGhassan KAbou-AlfaMDijProfBaek-YeolRyooMDa
doi : 10.1016/S1470-2045(21)00486-1
Volume 22, Issue 11, November 2021, Pages 1560-1572
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Jennifer JGaoMDa*JoyceChengPhDb*Tatiana MProwellMDc*ErikBloomquistPhDbShenghuiTangPhDbSuparna BWedamMDcMelanieRoyceMDcDanielleKrolMDcChristyOsgoodMDcGwynnIsonMDcRajeshwariSridharaPhDaRichardPazdurMDacJulia ABeaverMDac†LalehAmiri-KordestaniMDc†
doi : 10.1016/S1470-2045(21)00472-1
Volume 22, Issue 11, November 2021, Pages 1573-1581
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
ProfThierryFaconMDaProfShaji KKumarMDbProfTorbenPlesnerMDcRobert ZOrlowskiMDdProfPhilippeMoreauMDeProfNizarBahlisMDfProfSupratikBasuMDgHarethNahiMDhCyrilleHulinMDiHangQuachMDjProfHartmutGoldschmidtMDkProfMichaelO'DwyerMDlAurorePerrotMDmChristopher PVennerMDnProfKatjaWeiselMDoJoseph RMaceMDpProfNoopurRajeMDqMouradTiabMDrMargaretMacroMDsLaurentFrenzelMDtProfXavierLeleuMDuTahamtanAhmadiMDvJianpingWangPhDwRianVan RampelberghMDxClarissa MUhlarPhDyBrendaTrompMSczMariaDelioukinaMDyJessicaVermeulenMDzProfSaad ZUsmaniMDaa
doi : 10.1016/S1470-2045(21)00466-6
Volume 22, Issue 11, November 2021, Pages 1582-1596
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
Courtney DDiNardoMDaAndre CSchuhMDbEytan MSteinMDcPauMontesinosMDdAndrew HWeiMBBSeStéphanede BottonMDfAmer MZeidanMBBSgAmir TFathiMDhHagop MKantarjianMDaJohn MBennettMDiMark GFrattiniMDjPatriciaMartin-RegueiraMDjFrederikLerschRNkJingGongPhDjMaroofHasanMDjPareshVyasMDl†ProfHartmutDöhnerMDm†
doi : 10.1016/S1470-2045(21)00494-0
Volume 22, Issue 11, November 2021, Pages 1597-1608
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
HongyanChengPhDaLijuZongPhDaYujiaKongMDaXiaoyuWangMDaYuGuPhDaWeiCangPhDaProfJunZhaoMDaProfXirunWanMDaProfJunjunYangMDa*ProfYangXiangMDa*
doi : 10.1016/S1470-2045(21)00460-5
Volume 22, Issue 11, November 2021, Pages 1609-1617
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
Elizabeth KBancroftPhDab*Elizabeth CPageMSca*Mark NBrookPhDaSarahThomasMScbNatalieTaylorRNbJenniferPopeaJanaMcHughMBChBaAnn-BrittJonesMRCPaQuestaKarlssonPhDaSusanMersonBScaKai RenOngMDcJonathanHoffmanBMedSccCamillaHuberMSccLoviseMaehleMDdEli MarieGrindedalPhDdAstridStormorkenPhDdD GarethEvansMDeJeanetteRothwelleFionaLallooMDeAngela FBradyPhDfMarionBartlettMScfKatieSnapePhDgHelenHansonMDgPaulJamesPhDhijJoanneMcKinleyBSchLyonMascarenhasMSchSapnaSyngalMDklChineduUkaegbuMBBSkLucySideMDmnTessyThomasBScmnJulianBarwellPhDopManuel RTeixeiraPhDqrLouiseIzattPhDsMohnishSuriMDtFinlay AMacraeMDjuvNicolaPoplawskiMDwxRakefetChen-ShtoyermanPhDyzMunazaAhmedFRCPaaHannahMusgraveMScabNicolaNicolaiMDacLynnGreenhalghMScadCaroleBrewerMBBSaeafNicholasPachterMBChBagahAllan DSpigelmanMDaiajakAshrafAzzabiMDalBrian THelfandMDamDorothyHallidayPhDanSaundraBuysMDaoTeresaRamon y CajalMDapAlanDonaldsonMBChBaqKathleen ACooneyMDarMarionHarrisMBBSasatJohnMcGrathFRCSafauRosemarieDavidsonMBChBavAmyTaylorPhDawPeterCookeMDaxKathrynMyhillMScbMatthewHogbenBScbNeil KAaronsonPhDayAudreyArdern-JonesMScbChris HBangmaMDazElenaCastroPhDbaDavidDearnaleyFRCPbbAlexanderDiasMDbcTimDudderidgeMDmDiana MEcclesMDnbdKateGreenMPhileJorunnEyfjordDPhilbeAlisonFalconerFRCRbfChristopher SFosterMDbgHenrikGronbergPhDbhFreddie CHamdyFMedScibibjOskarJohannssonMDbkVincentKhooMDbgjbbHansLiljaMDblbmGeoffrey JLindemanPhDjubnJanLubinskiMDboKarolAxcronaPhDbpChristosMikropoulosMDbqAnita VMitraMDbrClareMoynihanMScaHollyNi RaghallaighMBChBaGadRennertMDbsRebeccaCollierMSct
doi : 10.1016/S1470-2045(21)00522-2
Volume 22, Issue 11, November 2021, Pages 1618-1631
National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis
CatherineDugganPhDaDarioTrapaniMDbcdAndré MIlbawiMDbElenaFidarovaMDbMathieuLaversanneMSceGiuseppeCuriglianoMDcdFreddieBrayPhDeProfBenjamin OAndersonMDabf
doi : 10.1016/S1470-2045(21)00462-9
Volume 22, Issue 11, November 2021, Pages 1632-1642
Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward
Carlos HBarriosMDabGustavoWerutskyMDbAlejandroMoharScDcAna SFerrignoMDdBettina GMüllerMDeBrittany LBychkovskyMDfghCarlos JoséCastro EMDiClaudia JUribeMDjCynthiaVillarreal-GarzaMDdEnriqueSoto-Perez-de-CelisMDkFranciscoGutiérrez-DelgadoPhDmnJi SeokKimBSgoJuliaIsmaelMDpProfLuciaDelgadoMDqrLuiz ASantiniMDsNelsonTeichMDtPamela CChavezMDuPedro E RLiedkeMDabvwPedroExmanMDxRomualdoBarroso-SousaPhDyStephen DStefaniMDaSuyapa A BejaranoCáceresMDzaaTaiane FRebelattoMDbTaniaPastranaPhDabYaninChavarri-GuerraMDlYolandaVargasMDacEduardoCazapPhDad
doi : 10.1016/S1470-2045(21)00492-7
Volume 22, Issue 11, November 2021, Pages e474-e487
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
GustavoWerutskyMDaCarlos HBarriosMDabAndres FCardonaPhDefgAndréAlbergariaPhDhAlfonsoValenciaMDiCarlos GFerreiraPhDdChristianRolfoPhDjEvandrode AzambujaPhDkGabriel ARabinovichPhDlGeorginaSposettiMDmnOscarArrietaMDoRodrigoDienstmannMDcTaiane FRebelattoMDaValeriaDenninghoffPhDpVeronicaAranPhDqEduardoCazapPhDr
doi : 10.1016/S1470-2045(21)00523-4
Volume 22, Issue 11, November 2021, Pages e488-e500
Revisiting neoadjuvant therapy in non-small-cell lung cancer
Stephanie P LSawMDaBoon-HeanOngMDcKevin L MChuaMDbAngelaTakanoMDdDaniel S WTanPhDae
doi : 10.1016/S1470-2045(21)00383-1
Volume 22, Issue 11, November 2021, Pages e501-e516
National cancer control plans across the Eastern Mediterranean region: challenges and opportunities to scale-up
IbtihalFadhilPhDaEmanAlkhalawiPhDbcRihabNasrPhDdHebaFouadPhDeParthaBasuPhDfRolandoCamachoMDgHafsaAlsaadoonBPharma
doi : 10.1016/S1470-2045(21)00410-1
Volume 22, Issue 11, November 2021, Pages e517-e529
A growing vulvar mass in a post-menopausal woman
YouhengXieMDaDanilo Giffoni M MMataMDcWeei-YuarnHuangMDadBojanaDjordjevicMDadKatarzyna JoannaJerzakMDbc
doi : 10.1016/S1470-2045(21)00521-0
Volume 22, Issue 11, November 2021, Page e530
